AptarGroup has announced the development of a dual-active material science technology designed to simultaneously control moisture and oxygen degradation in pharmaceutical drugs, with particular applications for oral solid dose glucagon-like peptide-1 (GLP-1) medications and medical devices. The technology represents what the company describes as a significant material science breakthrough in the pharmaceutical industry.
Technology Innovation
The new solution extends Aptar CSP Technologies' existing 3-Phase Activ-Polymer™ technology into applications where combined humidity and oxidation can compromise drug efficacy, safety, and shelf life. According to Badre Hammond, Vice President Commercial Operations and General Manager at Aptar CSP Technologies, "There has never been a singular, standalone active material aimed at protecting against both oxidation and moisture-related degradation at this level of precision across multiple platforms."
The technology addresses degradation challenges across multiple pharmaceutical formats, including oral solid dose drugs, medical devices, implantable mesh devices, microarray patches, and transdermal delivery systems. Hammond noted that the launch "reflects years of development, engineering excellence, and a deep understanding of our customers' most pressing stability challenges."
Regulatory and Commercial Applications
Aptar's dual-active technology can be customized for various product formats and development stages, from early research and development through commercial launch. The company states that the technology helps support regulatory compliance and product protection across multiple formats, aimed at helping pharmaceutical companies meet strict International Council for Harmonization (ICH) stability requirements while maintaining performance and integrity of sensitive drug or device components.
GLP-1 Drug Applications
Beyond the protection technology for oral solid dose GLP-1 drugs, Aptar offers complementary elastomeric components for GLP-1 drug products, including plungers and rigid needle shields. The company reports that pharmaceutical companies have validated Aptar's elastomeric components and are partnering with the company to develop injectable solutions for GLP-1 medications.
By integrating digital technologies with patient services, Aptar provides what it describes as fully integrated solutions designed to help drug manufacturers create differentiated drug delivery systems and enhance patient experiences for GLP-1 and other therapeutic applications.
Company Background
AptarGroup serves multiple end markets including pharmaceutical, beauty, food, beverage, personal care, and home care sectors. Aptar CSP Technologies leverages active material science expertise to transform concepts into market opportunities while providing comprehensive services from concept ideation through regulatory support. The company is headquartered in Crystal Lake, Illinois, and employs over 13,000 people across 20 countries.
